Please assess the completion status of the following clinical trial:

Trial Title: Specimen Collection Study From Coronavirus Disease 2019 (COVID-19) Vaccinated Adults and Adolescents

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant (by participant report) female adults (≥18 years or older) or adolescents (≥12 years old and \<18 years old) in generally good health, who will receive a locally licensed or authorized COVID-19 vaccine, development of which was supported by the United States Government, as part of standard preventive medical care.~* Able to understand and sign the Informed Consent Form (for adolescent participants informed consent form from parent and participant assent).~* Participants with some medical conditions that might otherwise disqualify them from routine blood or blood component donations, such as HIV/AIDS, diabetes mellitus, etc., can participate if their conditions are stable, well-controlled, have had no change in clinical status or medication for at least 6 months, and whose participation in the protocol would not present excess risk to the participant as judged by the Investigator.~* Willing to comply with study procedures and schedule for sample collections.~* Available for follow-up visits over the next year.~For individuals willing to undergo leukapheresis procedure(s), Adults ≥18 years, and adolescents ≥12-17 years must meet the following minimum criteria:~* Weight ≥110 pounds/50 kg~* Platelet count \>150×109/L~* Adequate bilateral antecubital veins to allow for 2 peripheral vein access points.~* At least 2 weeks since any previous blood product donation.~Exclusion Criteria:~* Prior receipt of any COVID-19 vaccine.~* Anemia at screening, or history of anemia caused by chronic therapies or congenital/genetic conditions (e.g., thalassemia) per participant/parent report. Individuals with histories of anemias that have been remedied with treatment (e.g., parasitism, B12, iron deficiency) are allowed.~* Have a history of intravenous drug abuse.~* Have a history of sickle cell disease per participant/parent report~* Have a history of poorly controlled or clinically significant heart, lung, kidney disease, per participant/parent report and Investigator assessment.~* Have a history of Hepatitis B or C, per participant/parent report. Participants with resolved Hepatitis B or C, or those with no apparent clinical manifestations of these infections, may participate.~* Have a contraindication to phlebotomy (i.e., evidence of cellulitis or abscess; venous thrombosis on palpation; presence of hematoma; presence of vascular shunt, graft, or access device; anti-coagulation therapy; history of bleeding diathesis; or clinically significant thrombocytopenia (platelet count \<150×109/L) as assessed by Investigator, participant/parent report, or screening platelet count.~* Have a history of untreated, unresolved, or recurrent malaria during the preceding 12 months per participant/parent report.~* Have donated blood in the past 8 weeks.~* Have planned surgery in the next 8 weeks.~* Is breast feeding, pregnant, or may be pregnant, per participant report.~* Are currently participating or are planning to participate in any clinical trial, including a COVID-19 vaccine trial or COVID-19 therapeutic trial.~* Any condition that, in the opinion of the Investigator, would make study participation unsafe or would interfere with the objectives of the study.~* Any condition that in the judgement of the Investigator precludes participation because it could adversely affect participant safety or data integrity.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues